Drug Profile
Research programme: immunomodulatory therapeutics - Innovimmune Biotherapeutics
Alternative Names: INV-33Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Innovimmune Biotherapeutics
- Class Anti-inflammatories; Hepatoprotectants; Small molecules
- Mechanism of Action Immunomodulators; Macrophage migration inhibitory factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Autoimmune disorders; Non-alcoholic steatohepatitis
- Discontinued Asthma; Atherosclerosis; Inflammation; Inflammatory bowel diseases; Metabolic disorders
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in USA
- 28 Dec 2021 No recent reports of development identified for research development in Autoimmune-disorders in USA (PO)
- 01 Jan 2018 Early research in Non-alcoholic steatohepatitis in USA (unspecified route) (Innovimmune Biotherapeutics pipeline, February 2018)